skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structure;#8208;Based Design of Selective Noncovalent CDK12 Inhibitors

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; ; ; ; ;  [1] « less
  1. Pharmaron Beijing
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
INDUSTRY
OSTI Identifier:
1523525
Resource Type:
Journal Article
Journal Name:
ChemMedChem
Additional Journal Information:
Journal Volume: 13; Journal Issue: (3) ; 02, 2018
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Johannes, Jeffrey W., Denz, Christopher R., Su, Nancy, Wu, Allan, Impastato, Anna C., Mlynarski, Scott, Varnes, Jeffrey G., Prince, D. Bryan, Cidado, Justin, Gao, Ning, Haddrick, Malcolm, Jones, Natalie H., Li, Shaobin, Li, Xiuwei, Liu, Yang, Nguyen, Toan B., O,, Connell, Nichole, Rivers, Emma, Robbins, Daniel W., Tomlinson, Ronald, Yao, Tieguang, Zhu, Xiahui, Ferguson, Andrew D., Lamb, Michelle L., Manchester, John I., Guichard, Sylvie, and AstraZeneca). Structure;#8208;Based Design of Selective Noncovalent CDK12 Inhibitors. United States: N. p., 2019. Web. doi:10.1002/cmdc.201700695.
Johannes, Jeffrey W., Denz, Christopher R., Su, Nancy, Wu, Allan, Impastato, Anna C., Mlynarski, Scott, Varnes, Jeffrey G., Prince, D. Bryan, Cidado, Justin, Gao, Ning, Haddrick, Malcolm, Jones, Natalie H., Li, Shaobin, Li, Xiuwei, Liu, Yang, Nguyen, Toan B., O,, Connell, Nichole, Rivers, Emma, Robbins, Daniel W., Tomlinson, Ronald, Yao, Tieguang, Zhu, Xiahui, Ferguson, Andrew D., Lamb, Michelle L., Manchester, John I., Guichard, Sylvie, & AstraZeneca). Structure;#8208;Based Design of Selective Noncovalent CDK12 Inhibitors. United States. doi:10.1002/cmdc.201700695.
Johannes, Jeffrey W., Denz, Christopher R., Su, Nancy, Wu, Allan, Impastato, Anna C., Mlynarski, Scott, Varnes, Jeffrey G., Prince, D. Bryan, Cidado, Justin, Gao, Ning, Haddrick, Malcolm, Jones, Natalie H., Li, Shaobin, Li, Xiuwei, Liu, Yang, Nguyen, Toan B., O,, Connell, Nichole, Rivers, Emma, Robbins, Daniel W., Tomlinson, Ronald, Yao, Tieguang, Zhu, Xiahui, Ferguson, Andrew D., Lamb, Michelle L., Manchester, John I., Guichard, Sylvie, and AstraZeneca). Fri . "Structure;#8208;Based Design of Selective Noncovalent CDK12 Inhibitors". United States. doi:10.1002/cmdc.201700695.
@article{osti_1523525,
title = {Structure;#8208;Based Design of Selective Noncovalent CDK12 Inhibitors},
author = {Johannes, Jeffrey W. and Denz, Christopher R. and Su, Nancy and Wu, Allan and Impastato, Anna C. and Mlynarski, Scott and Varnes, Jeffrey G. and Prince, D. Bryan and Cidado, Justin and Gao, Ning and Haddrick, Malcolm and Jones, Natalie H. and Li, Shaobin and Li, Xiuwei and Liu, Yang and Nguyen, Toan B. and O, and Connell, Nichole and Rivers, Emma and Robbins, Daniel W. and Tomlinson, Ronald and Yao, Tieguang and Zhu, Xiahui and Ferguson, Andrew D. and Lamb, Michelle L. and Manchester, John I. and Guichard, Sylvie and AstraZeneca)},
abstractNote = {},
doi = {10.1002/cmdc.201700695},
journal = {ChemMedChem},
number = (3) ; 02, 2018,
volume = 13,
place = {United States},
year = {2019},
month = {5}
}

Works referenced in this record:

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
journal, August 2016

  • Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M.
  • Nature Chemical Biology, Vol. 12, Issue 10
  • DOI: 10.1038/nchembio.2166

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
journal, May 2010

  • Paruch, Kamil; Dwyer, Michael P.; Alvarez, Carmen
  • ACS Medicinal Chemistry Letters, Vol. 1, Issue 5
  • DOI: 10.1021/ml100051d

Targeting the DNA Damage Response in Cancer
journal, November 2015


The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
journal, October 2011

  • Blazek, D.; Kohoutek, J.; Bartholomeeusen, K.
  • Genes & Development, Vol. 25, Issue 20
  • DOI: 10.1101/gad.16962311

CDK inhibitors in cancer therapy: what is next?
journal, January 2008

  • Malumbres, Marcos; Pevarello, Paolo; Barbacid, Mariano
  • Trends in Pharmacological Sciences, Vol. 29, Issue 1
  • DOI: 10.1016/j.tips.2007.10.012

Cyclin-dependent kinases
journal, January 2014

  • Malumbres, Marcos
  • Genome Biology, Vol. 15, Issue 6
  • DOI: 10.1186/gb4184

Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties
journal, August 2013

  • Bibian, Mathieu; Rahaim, Ronald J.; Choi, Jun Yong
  • Bioorganic & Medicinal Chemistry Letters, Vol. 23, Issue 15
  • DOI: 10.1016/j.bmcl.2013.05.075

Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex
journal, February 2015

  • Ekumi, Kingsley M.; Paculova, Hana; Lenasi, Tina
  • Nucleic Acids Research, Vol. 43, Issue 5
  • DOI: 10.1093/nar/gkv101

Cyclin K goes with Cdk12 and Cdk13
journal, January 2012


Structures of the CDK12/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding
journal, November 2015

  • Dixon-Clarke, Sarah E.; Elkins, Jonathan M.; Cheng, S. -W. Grace
  • Scientific Reports, Vol. 5, Issue 1
  • DOI: 10.1038/srep17122

The structure and substrate specificity of human Cdk12/Cyclin K
journal, March 2014

  • Bösken, Christian A.; Farnung, Lucas; Hintermair, Corinna
  • Nature Communications, Vol. 5, Issue 1
  • DOI: 10.1038/ncomms4505

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
journal, October 2016


Structural and Functional Analysis of the Cdk13/Cyclin K Complex
journal, January 2016


Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
journal, November 2013


Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
journal, September 2013

  • Martin, Mathew P.; Olesen, Sanne H.; Georg, Gunda I.
  • ACS Chemical Biology, Vol. 8, Issue 11
  • DOI: 10.1021/cb4003283

Casein Kinase I
journal, November 1998


Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
journal, March 2015

  • Malínková, Veronika; Vylíčil, Jakub; Kryštof, Vladimír
  • Expert Opinion on Therapeutic Patents, Vol. 25, Issue 9
  • DOI: 10.1517/13543776.2015.1045414

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
journal, November 2016


Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
journal, June 2008


The history and future of targeting cyclin-dependent kinases in cancer therapy
journal, January 2015

  • Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.
  • Nature Reviews Drug Discovery, Vol. 14, Issue 2
  • DOI: 10.1038/nrd4504

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
journal, August 2016